Monte Rosa Therapeutics (GLUE) Receivables - Other: 2023-2025
Historic Receivables - Other for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $5.0 million.
- Monte Rosa Therapeutics' Receivables - Other rose 734.45% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 734.45%. This contributed to the annual value of $173,000 for FY2024, which is 65.74% down from last year.
- According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Receivables - Other is $5.0 million, which was up 109.49% from $2.4 million recorded in Q2 2025.
- Over the past 5 years, Monte Rosa Therapeutics' Receivables - Other peaked at $5.0 million during Q3 2025, and registered a low of $173,000 during Q4 2024.
- For the 3-year period, Monte Rosa Therapeutics' Receivables - Other averaged around $1.4 million, with its median value being $842,000 (2024).
- As far as peak fluctuations go, Monte Rosa Therapeutics' Receivables - Other tumbled by 72.30% in 2024, and later skyrocketed by 734.45% in 2025.
- Monte Rosa Therapeutics' Receivables - Other (Quarterly) stood at $505,000 in 2023, then plummeted by 65.74% to $173,000 in 2024, then surged by 734.45% to $5.0 million in 2025.
- Its last three reported values are $5.0 million in Q3 2025, $2.4 million for Q2 2025, and $1.4 million during Q1 2025.